Teplizumab treatment addresses underlying cause of Type 1
Shares of Precigen have increased after the company’s Phase 1b/2a study of its AG019 ActoBiotics, designed to address the underlying cause of Type 1 diabetes.
Shares of Precigen have increased after the company’s Phase 1b/2a study of its AG019 ActoBiotics, designed to address the underlying cause of Type 1 diabetes.
A drug that targets the immune system can delay Type 1 diabetes on average by two years in children and adults at high risk, according